Nanovery is challenging the dominance of PCR (US$37Bn market including COVID) for the detection of nucleic acids. We use DNA nanorobots in a simple, single step test without enzymes or temperature cycling. The company recently raised a total of £1.85m and has about a 15-month runway (without commercial deals).